Novo Nordisk has initiated legal proceedings against telehealth company Hims & Hers Health Inc., alleging the unauthorized marketing of compounded versions of its GLP-1 medications, including Wegovy and Ozempic. The lawsuit, filed in Delaware federal court, seeks to halt the sale of these products and claims damages for patent infringement.
The dispute centers on Hims & Hers’ recent introduction of a compounded semaglutide pill, priced at $49 for the first month and $99 monthly thereafter, significantly undercutting Novo Nordisk’s pricing. This move prompted Novo Nordisk to label the product as an “unapproved, inauthentic, and untested knockoff” of semaglutide, the active ingredient in Wegovy. ([apnews.com](https://apnews.com/article/d35e529de153c2df263ac10501584999?utm_source=openai))
In response to the lawsuit and regulatory scrutiny, Hims & Hers announced the withdrawal of its compounded GLP-1 pill just two days after its launch. The company cited industry discussions and regulatory considerations as factors in its decision. ([apnews.com](https://apnews.com/article/74eb9395c44acd8bb1e12350cb32c146?utm_source=openai))
Novo Nordisk’s legal action underscores concerns about patient safety and the integrity of the drug approval process. The company emphasized that compounded semaglutide products may contain dangerous impurities or incorrect amounts of active ingredients, potentially leading to severe health risks. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/02/09/3234381/0/en/Novo-Nordisk-takes-legal-action-against-Hims-Hers-to-protect-patients-from-unsafe-knock-off-Wegovy-and-Ozempic.html?utm_source=openai))
This lawsuit follows the termination of a collaboration between Novo Nordisk and Hims & Hers in June 2025. Novo Nordisk ended the partnership, accusing Hims & Hers of engaging in “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” ([cbsnews.com](https://www.cbsnews.com/news/novo-nordisk-hims-hers-wegovy-weight-loss-drugs/?utm_source=openai))
The case highlights the ongoing legal and regulatory challenges in the rapidly evolving market for GLP-1 medications, as companies navigate the balance between innovation, patient safety, and intellectual property rights.